- Home
- BUSE vs BLTE Comparison
BUSE vs BLTE Comparison
Compare BUSE & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- BLTE
- Stock Information
- Founded
- BUSE 1868
- BLTE 2018
- Country
- BUSE United States
- BLTE United States
- Employees
- BUSE N/A
- BLTE N/A
- Industry
- BUSE Major Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- BUSE Finance
- BLTE Health Care
- Exchange
- BUSE Nasdaq
- BLTE Nasdaq
- Market Cap
- BUSE 1.4B
- BLTE 1.5B
- IPO Year
- BUSE N/A
- BLTE 2022
- Fundamental
- Price
- BUSE $26.57
- BLTE $48.63
- Analyst Decision
- BUSE Buy
- BLTE Strong Buy
- Analyst Count
- BUSE 5
- BLTE 4
- Target Price
- BUSE $28.60
- BLTE $59.00
- AVG Volume (30 Days)
- BUSE 432.2K
- BLTE 25.0K
- Earning Date
- BUSE 10-22-2024
- BLTE 08-09-2024
- Dividend Yield
- BUSE 3.65%
- BLTE N/A
- EPS Growth
- BUSE N/A
- BLTE N/A
- EPS
- BUSE 1.94
- BLTE N/A
- Revenue
- BUSE $436,316,000.00
- BLTE N/A
- Revenue This Year
- BUSE N/A
- BLTE N/A
- Revenue Next Year
- BUSE $56.44
- BLTE N/A
- P/E Ratio
- BUSE $13.57
- BLTE N/A
- Revenue Growth
- BUSE N/A
- BLTE N/A
- 52 Week Low
- BUSE $17.51
- BLTE $28.51
- 52 Week High
- BUSE $28.97
- BLTE $50.66
- Technical
- Relative Strength Index (RSI)
- BUSE 52.38
- BLTE 50.69
- Support Level
- BUSE $25.26
- BLTE $46.90
- Resistance Level
- BUSE $26.34
- BLTE $48.98
- Average True Range (ATR)
- BUSE 0.60
- BLTE 1.00
- MACD
- BUSE -0.08
- BLTE -0.02
- Stochastic Oscillator
- BUSE 50.44
- BLTE 89.33
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.